Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer
NCT05951179Phase 2Recruiting
- Sponsor
- Protara Therapeutics
- Start
- Sep 2023
- Primary completion
- Oct 2031
- Modality
- Cell Therapies
- Countries
- 7
01
Overview
A Phase 2 trial of TARA-002 in non-muscle-invasive bladder cancer (NMIBC), sponsored by Protara Therapeutics. Started Sep 2023; status: recruiting.
02
Drugs
TARA-002
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05951179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05951179.